The ADC m906PBD targeting CD56 bound to the membrane-distal N-terminal IgG-like domains was much more potent than m900PBD bound to membrane-proximal domains for neuroblastoma cells, although the two antibodies share similar affinities in vitro40. This evidence concerns the gene NCAM1 and neuroblastoma.